Indication
Pyoderma gangrenosum
Pyoderma gangrenosum is a rare, non-infectious inflammatory cutaneous disorder classified within the spectrum of neutrophilic dermatoses. Read more about Pyoderma gangrenosum
833 drugs 198 manufacturers
Drugs that treat it
Common Pyoderma gangrenosum therapies.
DESONIDE
TRIAMCINOLONE ACETONIDE
DESOXIMETASONE
DESONIDE
DESONIDE
PREDNICARBATE
PSORCON (diflorasone diacetate)
PREPARATION H (hydrocortisone)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPyoderma gangrenosum is a rare, non-infectious inflammatory cutaneous disorder classified within the spectrum of neutrophilic dermatoses.
It primarily affects adults—most commonly in their 30s to 50s—and frequently occurs alongside systemic autoimmune conditions such as inflammatory bowel disease, rheumatoid arthritis, or hematologic malignancies.
Pathophysiologically driven by immune dysregulation, neutrophil dysfunction, and aberrant cytokine signaling, the condition is clinically characterized by painful, rapidly progressing skin pustules or nodules that break down into destructive ulcers with classic violaceous, undermined borders.
- nih.gov
Pyoderma gangrenosum is a rare, non-infectious inflammatory cutaneous disorder classified within the spectrum of neutrophilic dermatoses
- nih.gov
Pyoderma gangrenosum is a rare, non-infectious inflammatory cutaneous disorder classified within the spectrum of neutrophilic dermatoses
- nih.gov
It primarily affects adults—most commonly in their 30s to 50s—and frequently occurs alongside systemic autoimmune conditions such as inflammatory bowel disease, rheumatoid arthritis, or hematologic malignancies
- nih.gov
It primarily affects adults—most commonly in their 30s to 50s—and frequently occurs alongside systemic autoimmune conditions such as inflammatory bowel disease, rheumatoid arthritis, or hematologic malignancies
- nih.gov
Pathophysiologically driven by immune dysregulation, neutrophil dysfunction, and aberrant cytokine signaling, the condition is clinically characterized by painful, rapidly progressing skin pustules or nodules that break down into destructive ulcers with classic violaceous, undermined borders
- nih.gov
Pathophysiologically driven by immune dysregulation, neutrophil dysfunction, and aberrant cytokine signaling, the condition is clinically characterized by painful, rapidly progressing skin pustules or nodules that break down into destructive ulcers with classic violaceous, undermined borders
- nih.gov
Pathophysiologically driven by immune dysregulation, neutrophil dysfunction, and aberrant cytokine signaling, the condition is clinically characterized by painful, rapidly progressing skin pustules or nodules that break down into destructive ulcers with classic violaceous, undermined borders
Personalize your experience
Follow Pyoderma gangrenosum and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.